June 9, 2025 by AHNS Office An infographic presented by the AHNS Basic and Translational Science Service. The promise and uncertainties of applying the new neoadjuvant anti-PD1 standard created by KEYNOTE-689 #AHNS #AHNS #neoadjuvant #immunotherapy #HNSCC Share: Click to share on Facebook (Opens in new window) Facebook Click to share on X (Opens in new window) X Click to share on LinkedIn (Opens in new window) LinkedIn Related Category: AHNS News and Announcements About AHNS Office Previous Post:Immunotherapy in Mucosal HNSCC: Key Takeaways from the AHNS Webinar Next Post:Statement from the American Head and Neck Society in Support of Continued HPV Vaccination